Concordia Healthcare Corp. T.CXR.R

CXRX Bought Drugs To Jack up Prices

[GenericAdvocate]

Companies need to be held accountable for unethical pricing practices.  Pharmaceuticals are not ordinary market commodities.  Government will not allow the private sector to determine market dynames because there are access issues to patients.  If you are in Canada, you do not appreciate this problem because of your health care system.  But I guess that's why Concordia doesn't peddle their drugs in Canada since they can't price gouge there.  Instead, Canadians just got fleeced into buying their stock.

[cg16]

I think its unlikely that price increases will stop.  This is from last week: "In a statement, Valeant Pharmaceuticals (VRX -2.2%) says it has raised the wholesale acquisition prices of its neurology, gastrointestinal and urology products by 2 - 9% effective today."

[GenericAdvocate]

You have to look at their whole portfolio, just as you have to look at Concordia's entire portfolio.  Sure, Valeant and Concordia increased some drugs by a modest amount - drugs that they had competition in.  But when a company thinks they can increase a drug price by 1500% just because they have no competition  - and they think they are staying under the radar - they are wrong.

[cg16]

Why is Mylan coming with their own epi-pen generic?  

[Craigbad]

The thing is Valeant has a moat on many products so they have a certain amount of pricing power. Cxr on the other hand is more subject to market pressure from competitors. You don't have to look any further than Plaquenil where they took a big writedown, lowered prices and in the last Rbc report they said there has been further pricing pressure again.

[Craigbad]

Some of this could soon be rectified. The health bill in the UK is going for its second reading early next week and if it passes it should be law by spring. The company has not allowed for any price caps/rollbacks in their numbers and any prcing pressure could drastically affect target prices due to the leverage. The company was one of the main targets in The Times investigation which exposed the

[fundtrader]

dint you say that it was an excellent buy at 46$ with 0 risk of downside..cheapest pharma stock with less then 5 times debt ratio..Scammer

[Craigbad]

My buy target hit, on a $40 breakout, my sell target hit at $58. Management has destroyed the company since and I feel very mislead by them. Fool me once, shame on you, fool me twice, shame on me. 

[fundtrader]

there is a reason why lattice left. Your jig is up...time for you to leave as well